66000-42-8

Basic information

• Product Name: 1-(3,4-DICHLOROPHENYL)-4,5-DIHYDRO-1H-PYRAZOL-3-AMINE
• Synonyms: 1-(3,4-DICHLOROPHENYL)-4,5-DIHYDRO-1H-PYRAZOL-3-AMINE
• CAS NO: 66000-42-8
• Molecular Formula: C₉H₉Cl₂N₃
• Molecular Weight: 230.09
• Mol File: 66000-42-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 387.2±52.0 °C(Predicted)
• Appearance: /
• Density: 1.52±0.1 g/cm3(Predicted)
• PKA: 2.18±0.70(Predicted)
• CAS DataBase Reference: 1-(3,4-DICHLOROPHENYL)-4,5-DIHYDRO-1H-PYRAZOL-3-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,4-DICHLOROPHENYL)-4,5-DIHYDRO-1H-PYRAZOL-3-AMINE(66000-42-8)
• EPA Substance Registry System: 1-(3,4-DICHLOROPHENYL)-4,5-DIHYDRO-1H-PYRAZOL-3-AMINE(66000-42-8)

Safety Data

• Hazardous Substances Data: 66000-42-8(Hazardous Substances Data)

Upstream product

• 19763-90-7 3,4-dichlorophenylhydrazine hydrochloride 
• 107-13-1 acrylonitrile 

Downstream Products

• 946571-85-3 N-[1-(3,4-dichlorophenyl)-1 H-pyrazol-3-yl)-2-(piperidin-1-yl)acetamide 

Relevant articles and documents

Identification and Optimization of Novel Small c-Abl Kinase Activators Using Fragment and HTS Methodologies

Abelson kinase (c-Abl) is a ubiquitously expressed, nonreceptor tyrosine kinase which plays a key role in cell differentiation and survival. It was hypothesized that transient activation of c-Abl kinase via displacement of the N-terminal autoinhibitory "myristoyl latch", may lead to an increased hematopoietic stem cell differentiation. This would increase the numbers of circulating neutrophils and so be an effective treatment for chemotherapy-induced neutropenia. This paper describes the discovery and optimization of a thiazole series of novel small molecule c-Abl activators, initially identified by a high throughput screening. Subsequently, a scaffold-hop, which exploited the improved physicochemical properties of a dihydropyrazole analogue, identified through fragment screening, delivered potent, soluble, cell-active c-Abl activators, which demonstrated the intracellular activation of c-Abl in vivo.

Imidazole compounds having pharmaceutical activity towards the sigma receptor

The present invention relates to compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals.

3-Trifluoroacetylamino-1-aryl-2-pyrazolines

This disclosure describes novel 3-substituted amino-1-phenyl-2-pyrazolines and 3-substituted amino-1-mono and disubstituted phenyl-2-pyrazolines and their C4 and C5 analogs, useful for meliorating the inflammation and/or the progressive joint deterioration characteristic of arthritic disease, preventing the onset of asthmatic symptoms and allergic diseases, or as analgesic, antibacterial or antifungal agents.